⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program

Official Title: Assessment and Follow-up of Patients With Non-small Cell Lung Cancer (NSCLC) Treated With Nivolumab Under the French Temporary Authorization for Use (ATU) Program

Study ID: NCT02933346

Interventions

Study Description

Brief Summary: Our study sought to examine nivolumab efficacy and safety in advanced NSCLC patients treated under the Temporary Authorization for Use (ATU, compassionate use) setting and describe their long-term clinical characteristics, notably the treatments they received after nivolumab discontinuation. The profile of these patients shows greater conformity to that of a non-selected population, yet the clinical data collection does not reflect "real life" conditions and stops when treatment ends, which does not enable us to get an overview of post-immunotherapy treatments.

Detailed Description: Although the oncogene addiction concept has led to effective targeted treatments for certain histological non-small cell lung cancer (NSCLC) types, most patients with advanced tumors are still treated with first-line chemotherapy. In 2015, several studiess demonstrated the efficacy of nivolumab, an immunotherapy targeting immune checkpoints. In France, besides the clinical trials, this molecule has been made available in January 2015 under a Temporary Authorization for Use (ATU, compassionate use). Our study sought to examine nivolumab efficacy and safety in advanced NSCLC patients treated under the ATU setting and describe their long-term clinical characteristics, notably the treatments they received after nivolumab discontinuation. The profile of these patients shows greater conformity to that of a non-selected population, yet the clinical data collection does not reflect "real life" conditions and stops when treatment ends, which does not enable us to get an overview of post-immunotherapy treatments.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

CH du Pays d'Aix, Aix-En-Provence, , France

Clinique du Rambot, Aix-En-Provence, , France

CHU d'Amiens-Picardie, Amiens, , France

CHU d'Angers, Angers, , France

CH Argenteuil, Argenteuil, , France

CH d'Avignon, Avignon, , France

Institut Sainte Catherine, Avignon, , France

CH de la Côte Basque, Bayonne, , France

CHU de Besançon, Besançon, , France

CH de Blois, Blois, , France

Hôpital Avicenne APHP, Bobigny, , France

CH Briançon, Briançon, , France

Hôpital Pradel HCL, Bron, , France

Caen CLCC, Caen, , France

CHU de Caen, Caen, , France

CH de Pontoise, Cergy Pontoise, , France

CH Métropole Savoie, Chambéry, , France

HIA Percy, Clamart, , France

Centre Jean Perrin, Clermont-Ferrand, , France

CHU de Clermont-Ferrand, Clermont-Ferrand, , France

CH Alpes Léman, Contamine Sur Arve, , France

Clinique des Cèdres, Cornebarrieu, , France

CHI de Créteil, Créteil, , France

CH de Dax, Dax, , France

Centre Georges-François Leclerc, Dijon, , France

Institut Daniel Hollard, Grenoble, , France

CHR Saint-Omer, Helfaut, , France

CHU Grenoble Alpes, La Tronche, , France

CHD Vendée, La-Roche-Sur-Yon, , France

CH de Versailles, Le Chesnay, , France

Hôpital Bicêtre APHP, Le Kremlin Bicêtre, , France

CH Le Mans, Le Mans, , France

CHRU de Lille, Lille, , France

CHU de Limoges, Limoges, , France

Polyclinique de Limoges, Limoges, , France

Centre Léon Bérard, Lyon, , France

HP Clairval, Marseille, , France

Hôpital Nord APHM, Marseille, , France

HP Robert Schumann, Metz, , France

CH de Mont-De-Masan, Mont-De-Marsan, , France

CH de Belfort Montbéliard, Montbéliard, , France

GRH Mulhouse Sud-Alsace, Mulhouse, , France

Centre d'Oncologie de Gentilly, Nancy, , France

Nice CLCC, Nice, , France

CHU Nîmes, Nîmes, , France

CHR d'Orléans, Orléans, , France

Hegp Aphp, Paris, , France

HIA Val de Grâce, Paris, , France

Hôpital Saint Joseph, Paris, , France

Hôpital Saint Louis APHP, Paris, , France

Hôpital Tenon APHP, Paris, , France

CH de Pau, Pau, , France

CHU de Bordeaux, Pessac, , France

CH Lyon-Sud HCL, Pierre-Bénite, , France

CH de Saint-Brieuc, Saint-Brieuc, , France

CHU de Nantes, Saint-Herblain, , France

ICO René Gauducheau, Saint-Herblain, , France

CH Annecy Genevois, Saint-Julien-en-Genevois, , France

HIA Begin, Saint-Mandé, , France

ICL Lucien Neuwirth, Saint-Priest-en-Jarez, , France

NHC CHRU de Strasbourg, Strasbourg, , France

Hôpital Foch, Suresnes, , France

CHI Toulon La Seyne Sur Mer, Toulon, , France

HIA Saint Anne, Toulon, , France

CHU Toulouse, Toulouse, , France

CHRU de Tours, Tours, , France

Clinique Saint Joseph, Trélazé, , France

CH de Valence, Valence, , France

CHU Bretagne Atlantique, Vannes, , France

Hôpital Nord-Ouest, Villefranche-Sur-Saône, , France

Gustave Roussy, Villejuif, , France

Hôpital Paul Brousse APHP, Villejuif, , France

Contact Details

Name: Olivier MOLINIER, MD

Affiliation: CH Le Mans, France

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: